LYVE-1 Antibody (JF0979)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-66940

Recombinant Monoclonal Antibody.
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-66940
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

Flow Cytometry, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # JF0979

Concentration

1 mg/ml

View all LYVE-1 Antibodies »

Product Specifications

Immunogen

Synthetic peptide within Human LYVE-1 aa 36-72 / 322. (SwissProt: Q9Y5Y7 Human)

Localization

Membrane.

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Theoretical MW

35 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for LYVE-1 Antibody (JF0979)

LYVE-1 Antibody (JF0979)

Western Blot: LYVE-1 Antibody (JF0979) [NBP2-66940] -

Western Blot: LYVE-1 Antibody (JF0979) [NBP2-66940] - Western blot analysis of LYVE-1 on different lysates with Rabbit anti-LYVE1 antibody at 1/500 dilution.Lane 1: MCF-7 cell lysateLane 2: SW480 cell lysateLane 3: A431 cell lysateLane 4: HUVEC cell lysateLysates/proteins at 10 µg/Lane.Predicted band size: 35 kDaObserved band size: 35 kDaExposure time: 2 minutes;10% SDS-PAGE gel.Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody at 1/500 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:300,000 dilution was used for 1 hour at room temperature.
LYVE-1 Antibody (JF0979)

Western Blot: LYVE-1 Antibody (JF0979) [NBP2-66940] -

Western Blot: LYVE-1 Antibody (JF0979) [NBP2-66940] - Western blot analysis of LYVE-1 on different lysates with Rabbit anti-LYVE-1 antibody at 1/1,000 dilution.Lane 1: A549-si NT cell lysateLane 2: A549-si LYVE-1 cell lysateLysates/proteins at 10 µg/Lane.Predicted band size: 35 kDaObserved band size: 35 kDaExposure time: 3 minutes;4-20% SDS-PAGE gel.NBP2-66940 was shown to specifically react with LYVE-1 in A549-si NT cells. Weakened band was observed when A549-si LYVE-1 sample was tested. A549-si NT and Hela-si LYVE-1 samples were subjected to SDS-PAGE. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM in TBST for 1 hour at room temperature. The primary antibody (ET1702-29, 1/1,000) and Loading control antibody (Rabbit anti-GAPDH, 1/10,000) were used in 5% BSA at room temperature for 2 hours. Goat Anti-rabbit IgG-HRP Secondary Antibody at 1:100,000 dilution was used for 1 hour at room temperature.
Flow Cytometry: LYVE-1 Antibody (JF0979) [NBP2-66940]

Flow Cytometry: LYVE-1 Antibody (JF0979) [NBP2-66940]

Flow Cytometry: LYVE-1 Antibody (JF0979) [NBP2-66940] - Analysis of HUVEC cells with LYVE1 antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody

Applications for LYVE-1 Antibody (JF0979)

Application
Recommended Usage

Flow Cytometry

1:50-1:100

Western Blot

1:500-1:2000

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

TBS (pH7.4), 0.05% BSA, 40% Glycerol

Preservative

0.05% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: LYVE-1

LYVE-1 (Lymphatic Vessel Endothelial Receptor 1) is a receptor for the extracellular matrix mucopolysaccharide hyaluronan (HA) and is primarily expressed by lymphatic endothelial cells in addition to the sinusoidal endothelium of the liver and spleen (1-3). HA, also called hyaluronic acid, is a main component of the extracellular matrix and functions largely in cell adhesion, migration, and tissue remodeling (2). HA undergoes a turnover process that involves release from the tissues to the afferent lymph, degradation within the lymph nodes, and removal of fragments by the liver (2,3). LYVE-1, in addition to other lymphatic proteins including VEGFR3, Prox1, and podoplanin, is a common marker for differentiating between the blood and lymphatic systems (2,3). Furthermore, LYVE-1 is closely related to the leukocyte receptor CD44, having ~44% sequence similarity (1-3). Like CD44, the LYVE-1 protein contains an extracellular HA-binding link domain, with N- and C-terminal extensions, located at the end of a glycosylated juxtamembrane domain stalk region, followed by a transmembrane region, and a cytoplasmic tail (1-3). The key features of the HA-binding like molecule are the three disulfide bridges formed by six cysteine residues (1-3). LYVE-1 is synthesized as a protein of 322 amino acids in length with a theoretical molecular weight of 35 kDa, although due to O-glycosylation often appears in SDS-PAGE at a molecular weight ranging from ~60-70 kDa (2,4). The role of HA-binding is further elucidated by the identification of LYVE-1 as a docking receptor for dendritic cells and macrophages, binding their surface HA to control the entry and migration into lymph vessels (1).

LYVE-1 has been an important marker in studies of embryonic and tumor lymphangiogenesis, as many cancers are characterized by early metastasis to the lymph nodes (1-3, 5). One study of five different vascular tumors in infants used immunohistochemical analysis and found positive LYVE-1 expression in infantile hemangioma, tufted angioma, and kaposiform hemangioendothelioma (5). LYVE-1 along with other markers such as GLUT-1, CD31, CD34, Prox-1, and WT-1 can be used to help provide immunohistologic profiles of various tumors and, when used in conjunction with clinical and histopathologic approaches, may offer better overall diagnosis and disease treatment (5).

References

1. Jackson D. G. (2019). Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biology : Journal of the International Society for Matrix Biology. https://doi.org/10.1016/j.matbio.2018.02.001

2. Jackson D. G. (2004). Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. https://doi.org/10.1111/j.1600-0463.2004.apm11207-0811.x

3. Jackson D. G. (2003). The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends in Cardiovascular Medicine. https://doi.org/10.1016/s1050-1738(02)00189-5

4. Unitprot (Q9Y5Y7)

5. Johnson, E. F., Davis, D. M., Tollefson, M. M., Fritchie, K., & Gibson, L. E. (2018). Vascular Tumors in Infants: Case Report and Review of Clinical, Histopathologic, and Immunohistochemical Characteristics of Infantile Hemangioma, Pyogenic Granuloma, Noninvoluting Congenital Hemangioma, Tufted Angioma, and Kaposiform Hemangioendothelioma. The American Journal of Dermatopathology. https://doi.org/10.1097/DAD.0000000000000983

Long Name

Lymphatic Vessel Endothelial Hyaluronan Receptor 1

Alternate Names

LYVE1, XLKD1

Gene Symbol

LYVE1

Additional LYVE-1 Products

Product Documents for LYVE-1 Antibody (JF0979)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for LYVE-1 Antibody (JF0979)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.